17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception

Br J Pharmacol. 2012 Feb;165(3):683-92. doi: 10.1111/j.1476-5381.2011.01568.x.


Background and purpose: Transient receptor potential ion channel vanilloid 3 (TRPV3) is expressed in skin keratinocytes and plays an important role in thermal and chemical nociceptions in the periphery. The presence of TRPV3 inhibitors would improve our understanding of TRPV3 function and help to develop receptor-specific analgesics. However, little is known about physiological substances that specifically inhibit TRPV3 activity. Here, we investigated whether 17(R)-resolvin D1 (17R-RvD1), a naturally occurring pro-resolving lipid specifically affects TRPV3 activity.

Experimental approach: We examined the effect of 17R-RvD1 on sensory TRP channels using Ca(2+) imaging and whole cell electrophysiology experiments in a HEK cell heterologous expression system, cultured sensory neurons and keratinocytes. We also examined changes in sensory TRP agonist-specific acute licking/flicking or flinching behaviours and mechanical and thermal pain behaviours using Hargreaves, Randall-Selitto and von Frey assay systems in the absence and presence of inflammation.

Key results: We showed that 17R-RvD1 specifically suppresses TRPV3-mediated activity at nanomolar and micromolar concentrations. The voltage-dependence of TRPV3 activation by camphor was shifted rightwards by 17R-RvD1, which indicates its inhibitory mechanism is as a result of a shift in voltage-dependence. Consistently, TRPV3-specific acute pain behaviours were attenuated by locally injected 17R-RvD1. Moreover, the administration of 17R-RvD1 significantly reversed the thermal hypersensitivity that occurs during an inflammatory response. Knockdown of epidermal TRPV3 blunted these antinociceptive effects of 17R-RvD1.

Conclusions and implications: 17R-RvD1 is a novel natural inhibitory substance specific for TRPV3. The results of our behavioural studies suggest that 17R-RvD1 has acute analgesic potential via TRPV3-specific mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology
  • Analgesics / therapeutic use*
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Capsaicin
  • Carrageenan
  • Cell Line
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / therapeutic use*
  • Freund's Adjuvant
  • Ganglia, Spinal / cytology
  • HEK293 Cells
  • Hot Temperature
  • Humans
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Inflammation / physiopathology
  • Keratinocytes / drug effects
  • Keratinocytes / physiology
  • Male
  • Mice
  • Mice, Inbred ICR
  • Mice, Knockout
  • Pain / chemically induced
  • Pain / drug therapy*
  • Pain / physiopathology
  • Rats
  • Rats, Sprague-Dawley
  • Sensory Receptor Cells / drug effects
  • Sensory Receptor Cells / physiology
  • TRPV Cation Channels / antagonists & inhibitors*
  • TRPV Cation Channels / deficiency
  • TRPV Cation Channels / genetics
  • TRPV Cation Channels / physiology


  • Analgesics
  • Anti-Inflammatory Agents
  • TRPV Cation Channels
  • TRPV1 protein, mouse
  • TRPV3 protein, human
  • Trpv3 protein, mouse
  • resolvin D1
  • Docosahexaenoic Acids
  • Carrageenan
  • Freund's Adjuvant
  • Capsaicin